PMID- 23506519
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20181203
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 13
IP  - 6
DP  - 2013 Jun
TI  - Dermatologic adverse events associated with afatinib: an oral ErbB family 
      blocker.
PG  - 721-8
LID - 10.1586/era.13.30 [doi]
AB  - Dermatologic adverse events (AEs) are frequently observed in patients receiving 
      EGF receptor (EGFR; also known as ErbB1) tyrosine kinase inhibitor therapy. The 
      impact of these AEs goes beyond cosmesis to the discomfort from itching, pain and 
      secondary infections, all of which may significantly impact on patient 
      well-being, adherence and clinical outcomes. Afatinib is a potent, irreversible, 
      oral, ErbB family blocker, inhibiting EGFR (ErbB1), HER2 (ErbB2) and ErbB4 
      receptor kinases. It also inhibits transphosphorylation of ErbB3. Similar to EGFR 
      inhibitors, dermatologic AEs have been frequently observed in patients treated 
      with afatinib. Papulopustular (acneiform) rash, pruritus, xerosis, paronychia and 
      alopecia will require patient education and proactive treatment interventions. 
      This article summarizes current data on the dermatologic AEs associated with 
      afatinib treatment across the clinical trial program, and provides strategies for 
      their effective management.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Memorial Sloan-Kettering Cancer Center, New York, NY, USA. lacoutum@mskcc.org
FAU - Schadendorf, Dirk
AU  - Schadendorf D
FAU - Chu, Chia-Yu
AU  - Chu CY
FAU - Uttenreuther-Fischer, Martina
AU  - Uttenreuther-Fischer M
FAU - Stammberger, Uz
AU  - Stammberger U
FAU - O'Brien, Dennis
AU  - O'Brien D
FAU - Hauschild, Axel
AU  - Hauschild A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130318
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 41UD74L59M (Afatinib)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Administration, Oral
MH  - Afatinib
MH  - Alopecia/chemically induced
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Exanthema/chemically induced
MH  - Humans
MH  - Paronychia/chemically induced
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Pruritus/chemically induced
MH  - Quinazolines/*administration & dosage/*adverse effects
MH  - Receptor, ErbB-2/antagonists & inhibitors
EDAT- 2013/03/20 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/03/20 06:00
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - 10.1586/era.13.30 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2013 Jun;13(6):721-8. doi: 10.1586/era.13.30. Epub 
      2013 Mar 18.